Insight

Jun 8, 2024, 09:58

Angelo Pirozzi: Circulating immune-related proteins might predict the efficacy of Immune Checkpoint Inhibitors

Angelo Pirozzi, Research Fellow at Mayo Clinic, shared on X: .

“92 Circulating-immuno-oncology-related proteins in patients with metastatic PDAC (Pancreatic Ductal Adenocarcinoma) from the CheckPAC trial who responded to radiotherapy +nivolumab ± ipilimumab.

High FASLG (FAS ligand) and Gal-1 lead to higher PFS (progression-free survival)

Circulating immune-related proteins might predict the efficacy of ICIs (Immune Checkpoint Inhibitors).”

Proceed to the article.
Source: Angelo Pirozzi/X

Angelo Pirozzi cancer CheckPAC FASLG Immune checkpoint inhibitors (ICIs) immune-related proteins ipilimumab Mayo Clinic metastatic PDAC nivolumab OncoDaily Oncology pancreatic ductal adenocarcinoma PDAC PFS

Invest in Health Policy: A Conversation with Professor Andreas Charalambous

FDA Approves Cosibelimab-ipdl for Treatment of Metastatic or Locally Advanced Cutaneous Squamous Cell Carcinoma

Dolph Lundgren’s Fight for Life: How He Survived Kidney Cancer After 9 Years of Battle

Agenus and Tanner Pharma Partner to Expand Global Access to BOT/BAL

Bispecific Antibody M701 Offers a Novel Treatment Option for Malignant Ascites

Special Coverage